Oculex
Phase 3
UCBOculex is one of 30 therapeutic programs targeting Wet Age-Related Macular Degeneration. It is currently in Phase 3.
1
Indications
0
Total Trials
0
Active Trials
29
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
43 competitors in Wet Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Macugen
PfizerApproved
Eylea
RegeneronPhase 3
Lucentis
RochePhase 3
Avastin
BBio-Thera Solutions
Phase 3
Retaane
AAlcon Research
Phase 3
Inversine
TTargacept Inc.
Phase 2
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 2
Decadron
AAspen Global Incorporated
Phase 2
EYP-1901
EEyePoint Pharmaceuticals, Inc.
Phase 3
Lucentis
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Oculex. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3
- Company